Rapid In Vitro Multiplication of Non-Runnering \u3cem\u3eFragaria vesca\u3c/em\u3e Genotypes from Seedling Shoot Axillary Bud Explants

Fragaria vesca L. has become a model species for genomic studies relevant to important crop plant species in the Rosaceae family, but generating large numbers of plants from non-runner-producing genotypes is slow. To develop a protocol for the rapid generation of plants, leaf explants were compared to single axillary bud shoot explants, both from in vitro-grown Fragaria vesca seedlings, as sources of shoots for new plant production in response to benzyladenine (BA) or thidiazuron (TDZ) combined with indolebutyric acid (IBA) on Murashige and Skoog’s Basal Salt (MS) medium. BA at 2.0 and 4.0 mg L−1 and TDZ at 1.5 mg L−1 promoted the greatest number of shoots produced per shoot explant. There were no IBA effects or IBA interactions with BA or TDZ. Significant interactions between BA and IBA, but not TDZ and IBA, occurred in leaf explant callus formation and % explants with callus at 6 and 9 weeks of culture and on shoots per leaf explant at 9 weeks. TDZ treatments produced uniformly high levels of callus but low numbers of shoots. The treatment generating the most shoot production was BA at 4.0 mg L−1 plus IBA at 0.50 mg L−1. After 9 weeks of culture, leaf explants of the non-runner-producing genotype Baron Solemacher had generated 4.6 shoots per explant with the best treatment, while axillary bud explants had generated 30.8 shoots with the best treatment. Thus, in vitro culture of shoot axillary bud explants can generate high numbers of clonal shoots from a single seedling plant in vitro

Effect of angiotensin-converting enzyme inhibitor and angiotensin receptor blocker initiation on organ support-free days in patients hospitalized with COVID-19

IMPORTANCE Overactivation of the renin-angiotensin system (RAS) may contribute to poor clinical outcomes in patients with COVID-19. Objective To determine whether angiotensin-converting enzyme (ACE) inhibitor or angiotensin receptor blocker (ARB) initiation improves outcomes in patients hospitalized for COVID-19. DESIGN, SETTING, AND PARTICIPANTS In an ongoing, adaptive platform randomized clinical trial, 721 critically ill and 58 non–critically ill hospitalized adults were randomized to receive an RAS inhibitor or control between March 16, 2021, and February 25, 2022, at 69 sites in 7 countries (final follow-up on June 1, 2022). INTERVENTIONS Patients were randomized to receive open-label initiation of an ACE inhibitor (n = 257), ARB (n = 248), ARB in combination with DMX-200 (a chemokine receptor-2 inhibitor; n = 10), or no RAS inhibitor (control; n = 264) for up to 10 days. MAIN OUTCOMES AND MEASURES The primary outcome was organ support–free days, a composite of hospital survival and days alive without cardiovascular or respiratory organ support through 21 days. The primary analysis was a bayesian cumulative logistic model. Odds ratios (ORs) greater than 1 represent improved outcomes. RESULTS On February 25, 2022, enrollment was discontinued due to safety concerns. Among 679 critically ill patients with available primary outcome data, the median age was 56 years and 239 participants (35.2%) were women. Median (IQR) organ support–free days among critically ill patients was 10 (–1 to 16) in the ACE inhibitor group (n = 231), 8 (–1 to 17) in the ARB group (n = 217), and 12 (0 to 17) in the control group (n = 231) (median adjusted odds ratios of 0.77 [95% bayesian credible interval, 0.58-1.06] for improvement for ACE inhibitor and 0.76 [95% credible interval, 0.56-1.05] for ARB compared with control). The posterior probabilities that ACE inhibitors and ARBs worsened organ support–free days compared with control were 94.9% and 95.4%, respectively. Hospital survival occurred in 166 of 231 critically ill participants (71.9%) in the ACE inhibitor group, 152 of 217 (70.0%) in the ARB group, and 182 of 231 (78.8%) in the control group (posterior probabilities that ACE inhibitor and ARB worsened hospital survival compared with control were 95.3% and 98.1%, respectively). CONCLUSIONS AND RELEVANCE In this trial, among critically ill adults with COVID-19, initiation of an ACE inhibitor or ARB did not improve, and likely worsened, clinical outcomes. TRIAL REGISTRATION ClinicalTrials.gov Identifier: NCT0273570

A Laboratory Exercise in Physiological Seed Dormancy Using Eastern Redbud

A laboratory exercise is presented that demonstrates the impact of seed coverings and hormones on seed dormancy and release in seeds with endogenous, physiological dormancy. The materials and methods are simple and inexpensive and can be accomplished as an on-campus laboratory or as a distance education exercise. The execution of the laboratory is rapid (approximate to 1 hour), and the results are obtained in 2 weeks. The exercise generates an opportunity for the discussion of a complex subject that involves the interaction of two tissue types within the seed (the embryo vs. the seed coverings) and nicely illustrates their role in seed dormancy maintenance

A Laboratory Exercise in Physiological Seed Dormancy Using Eastern Redbud

A laboratory exercise is presented that demonstrates the impact of seed coverings and hormones on seed dormancy and release in seeds with endogenous, physiological dormancy. The materials and methods are simple and inexpensive and can be accomplished as an on-campus laboratory or as a distance education exercise. The execution of the laboratory is rapid (approximate to 1 hour), and the results are obtained in 2 weeks. The exercise generates an opportunity for the discussion of a complex subject that involves the interaction of two tissue types within the seed (the embryo vs. the seed coverings) and nicely illustrates their role in seed dormancy maintenance

Seed Priming and Pericarp Removal Improve Germination in Low-Germinating Seed Lots of Industrial Hemp

Industrial hemp (Cannabis sativa L.) is experiencing a resurgence in North America as an agricultural commodity. Germplasm improvement for locally adapted and stable cannabinoid production is an industry priority. This study used seed priming and pericarp removal to recover seedlings in low-germinating seed lots that could prove important for plant breeding and germplasm conservation. Both seed priming and pericarp removal improved early seed germination, but pericarp removal was more effective in improving overall final germination percentages. On average, pericarp removal improved final germination in low-germinating seed lots by approximately 38% compared to intact seed germination. In seeds with the pericarp removed, the initial germination substrate had an impact on normal seedling development following transplanting: those germinated for 2 to 3 days on rolled towels produced more normal seedlings compared to those started in Petri dishes. There was a dramatic increase in abnormal seedlings produced in the low-germinating seed lot initially germinated in a Petri dish wetted with 6 mL water where nearly 80% never transitioned to normal actively growing seedlings

Temperature Limits for Seed Germination in Industrial Hemp (Cannabis sativa L.)

Industrial hemp (Cannabis sativa L.) as a grain and fiber crop is experiencing a resurgence in North America. Due to governmental prohibition, there has been limited information on regional agronomic production systems including basic information on seed germination. This study was initiated to provide basic information on the relationship between temperature and germination in hemp seed. Germination was measured at constant temperatures ranging from 3 to 42 °C. Cardinal temperatures were determined for two industrial oil crop hemp cultivars (‘Georgina’ and ‘Victoria’). The optimal germination temperature indicated by a high mean germination percentage and rate was between 19 and 30 °C. Optimal (29.6 °C), base (3.4 °C) and ceiling (42.6 °C) temperatures were calculated from a linear regression of the germination rates to reach 50% germination for each temperature. The thermal time for ‘Georgina’ and ‘Victoria’ to reach 50% germination at suboptimal temperatures was 694 and 714 °C h, respectively. The osmotic and solid matrix-primed hemp seeds germinated faster than the untreated seeds, but the final germination percentages were not different. The primed seeds germinated faster at supraoptimal temperatures but did not impact final germination percentages in the thermally inhibited seeds

The Effect of a Polysaccharide-Based Multinutrient Dietary Supplementation Regimen on Infections and Immune Functioning in Multiple Sclerosis

Multiple sclerosis (MS) is a progressive neurodegenerative disease associated with increased infection rates, chronic inflammation, and premature death. Optimization of nutritional status via dietary supplementation may improve immune function in people suffering from MS and lead to decreased rates of infection. Fifteen individuals with a diagnosis of relapsing-remitting MS for an average of 12.4 years (SD =7.4; R = 2, 25) were enrolled in a one-year open-label clinical trial. Participants consumed a broad-spectrum dietary supplement regimen containing polysaccharides, phytochemicals, antioxidants, vitamins, and minerals three times per day. The occurrence of infections and a panel of cytokines, growth factors, and T- and B-cell subsets were assessed at baseline and 12 months. Seven female and 8 male participants with an average age of 51.3 years (SD =7.2; R = 38, 65) completed the study. At the end of the intervention, participants had fewer total infections (M = 7.9, SD =8.1 at baseline and M = 2.5, SD =4.3 at 12-month follow-up). At 12 months, IL-2, TNF-α, EGF, and CD95 + CD34+ significantly increased, while IL-1β significantly decreased. No major adverse effects were reported; only mild gastrointestinal intolerance was reported in four cases. A decreased occurrence of infection was observed in MS patients treated with 12 months of a polysaccharide-based multinutrient dietary supplement. Significant changes were also noted in several key biomarkers that would be physiologically favorable to the MS population. Thus, the results of this study suggest an immunomodulatory effect of the dietary supplement regimen studied